Assessment of serum UCH-L1 and GFAP in acute stroke patients

Scientific Reports

Volumn 14, Issue 6, 2016, Pages

  Ren, Changhong ^a,b,c   Kobeissy, Firas ^d,e   Alawieh, Ali ^f   Li, Na ^a   Li, Ning ^a   Zibara, Kazem ^e,g   Zoltewicz, Susie ^h   Guingab Cagmat, Joy ^h   Larner, Stephen F ^h   Ding, Yuchuan ⁱ   Hayes, Ronald L ^h   Ji, Xunming ^a,b,c   Mondello, Stefania ^j  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Key Laboratory of Hypoxic Conditioning Translational Medicine   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g LEBANESE UNIVERSITY   (Lebanon)

^h BANYAN BIOMARKERS INC   (United States)

ⁱ WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF MESSINA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE L-1, HUMAN; UBIQUITIN THIOLESTERASE;

ADULT; AGED; BLOOD; CHEMISTRY; DIAGNOSTIC TEST; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; SERUM; STROKE; TIME FACTOR;

ADULT; AGED; DIAGNOSTIC TESTS, ROUTINE; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SERUM; STROKE; TIME FACTORS; UBIQUITIN THIOLESTERASE;

EID: 84975468882     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24588     Document Type: Article

References (44)

1. Murray, C. J. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2197-2223 (2012).
2. Whiteley, W. Identifying blood biomarkers to improve the diagnosis of stroke. J R Coll Physicians Edinb 41, 152-154 (2011).
3. Mouhieddine, T. H. et al. Nanotheragnostic applications for ischemic and hemorrhagic strokes: improved delivery for a better prognosis. Curr Neurol Neurosci Rep 15, 505 (2015).
4. Chalela, J. A. et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 369, 293-298 (2007).
5. Jauch, E. C. et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44, 870-947 (2013).
6. Foerch, C., Montaner, J., Furie, K. L., Ning, M. M. & Lo, E. H. Invited article: searching for oracles? Blood biomarkers in acute stroke. Neurology 73, 393-399 (2009).
7. Liu, M. C. et al. Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur J Neurosci 31, 722-732 (2010).
8. Eng, L. F., Ghirnikar, R. S. & Lee, Y. L. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 25, 1439-1451 (2000).
9. Foerch, C. et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry 77, 181-184 (2006).
10. Foerch, C. et al. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem 58, 237-245 (2012).
11. Mondello, S. et al. The challenge of mild traumatic brain injury: role of biochemical markers in diagnosis of brain damage. Med Res Rev 34, 503-531 (2014).
12. Jackson, P. & Thompson, R. J. The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis. J Neurol Sci 49, 429-438 (1981).
13. Papa, L. et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 38, 138-144 (2010).
14. Rojo, D. R. et al. Influence of stochastic gene expression on the cell survival rheostat after traumatic brain injury. Plos One 6, e23111 (2011).
15. Ren, C. et al. Different expression of ubiquitin C-terminal hydrolase-L1 and alphaII-spectrin in ischemic and hemorrhagic stroke: Potential biomarkers in diagnosis. Brain Res 1540, 84-91 (2013).
16. Papa, L. et al. Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg 72, 1335-1344 (2012).
17. Mondello, S. et al. Clinical Utility of Serum Levels of Ubiquitin C-Terminal Hydrolase as a Biomarker for Severe Traumatic Brain Injury. Neurosurgery 70, 666-675 (2012).
18. Mondello, S. et al. Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care 15, R156 (2011).
19. Mondello, S. et al. Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. J Neurotrauma 29, 1096-1104 (2012).
20. Kou, Z. et al. The Role of Advanced MR Imaging Findings as Biomarkers of Traumatic Brain Injury. J Head Trauma Rehabil 25, 267-282 (2010).
21. Papa, L. et al. Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med 59, 471-483 (2012).
22. Diaz-Arrastia, R. et al. Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma 31, 19-25 (2014).
23. Brouns, R. et al. Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic stroke patients. Clin Chem 56, 451-458 (2010).
24. Schiff, L., Hadker, N., Weiser, S. & Rausch, C. A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol Diagn Ther 16, 79-92 (2012).
25. Broderick, J. et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38, 2001-2023 (2007).
26. Dvorak, F., Haberer, I., Sitzer, M. & Foerch, C. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc Dis 27, 37-41 (2009).
27. Unden, J. et al. Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. J Neurol 256, 72-77 (2009).
28. Rodriguez-Yanez, M. & Castillo, J. Role of inflammatory markers in brain ischemia. Curr Opin Neurol 21, 353-357 (2008).
29. Olivot, J. M., Labreuche, J., Aiach, M., Amarenco, P. & Investigators, G. Soluble thrombomodulin and brain infarction: case-control and prospective study. Stroke 35, 1946-1951 (2004).
30. Barber, M., Langhorne, P., Rumley, A., Lowe, G. D. & Stott, D. J. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke 35, 1421-1425 (2004).
31. Tombul, T., Atbas, C. & Anlar, O. Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction. J Clin Neurosci 12, 429-434 (2005).
32. Sato, M., Suzuki, A., Nagata, K. & Uchiyama, S. Increased von Willebrand factor in acute stroke patients with atrial fibrillation. J Stroke Cerebrovasc Dis 15, 1-7 (2006).
33. Cano, C. P. et al. Increased serum malondialdehyde and decreased nitric oxide within 24 hours of thrombotic stroke onset. Am J Ther 10, 473-476 (2003).
34. Tso, A. W. et al. Serum adipocyte fatty acid-binding protein associated with ischemic stroke and early death. Neurology 76, 1968-1975 (2011).
35. George, P. M. et al. Novel TIA biomarkers identified by mass spectrometry-based proteomics. Int J Stroke 10, 1204-1211 (2015).
36. Dambinova, S. A., Khounteev, G. A. & Skoromets, A. A. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke 33, 1181-1182 (2002).
37. Brophy, G. M. et al. Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma 28, 861-870 (2011).
38. Zoltewicz, J. S. et al. Biomarkers Track Damage Following Graded Injury Severity in a Rat Model of Penetrating Brain Injury. J Neurotrauma 30, 1161-1169 (2013).
39. Mondello, S. et al. Insight into Pre-Clinical Models of Traumatic Brain Injury Using Circulating Brain Damage Biomarkers: Operation Brain Trauma Therapy. J Neurotrauma 33, 595-605 (2016).
40. Danton, G. H., Prado, R., Watson, B. D. & Dietrich, W. D. Temporal profile of enhanced vulnerability of the postthrombotic brain to secondary embolic events. Stroke 33, 1113-1119 (2002).
41. Vos, P. E., van Gils, M., Beems, T., Zimmerman, C. & Verbeek, M. M. Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity. Eur J Neurol 13, 632-638 (2006).
42. Button, K. S. et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 14, 365-376 (2013).
43. Furie, K. L. et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 42, 227-276 (2011).
44. Mondello, S. et al. CSF alpha-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism Relat Disord 20, 382-387 (2014).